Torka, P., Kelly, O., Levenstein, H., Douglas, M., Jacob, H., Truong, R., Eley, E., Moscoso, S., Boardman, A., Caron, P., David, K., Epstein-Peterson, Z., Falchi, L., Ghione, P., Horwitz, S., Zain, J., Zelenetz, A., Intlekofer, A., Johnson, W., Kumar, A., Lue, J., Luttwak, E., Moskowitz, A., Noy, A., Owens, C., Palomba, L., Steiner, R., Stuver, R., Vardhana, S., Salles, G., Hamlin, P. (2025). Epcoritamab with lenalidomide and tafasitamab in patients with relapsed/refractory diffuse large B cell lymphoma (ECLAT), a phase 2 investigator-initiated trial. Blood. https://doi.org/10.1182/blood-2025-1971